Product Description:
| Product Name |
GS-441524 |
| Expiry Date |
1 Year From The Date Of Manufacture |
| Storage Condition |
Room Temperature |
| CAS Number |
1191237-69-0 |
| Core Function |
Treatment For Cat FIP |
| Dosage Form |
Injection |
| Country of Manufacture |
China |
| Packaging Specs |
6ml/vial, 8ml/vial, 10ml/vial |
| Active Strength |
20mg, 30mg |
GS-441524 is a nucleoside analog with potent and specific antiviral activity against feline coronavirus (FCoV), the etiological agent of feline infectious peritonitis (FIP). The molecular mechanism of its antiviral action lies in its ability to target the RNA-dependent RNA polymerase of FCoV, an essential enzyme for the virus to complete intracellular replication. As a structural analog of natural nucleosides, GS-441524 is competitively incorporated into the viral RNA synthesis process by the viral polymerase, and due to the lack of a 3'-hydroxyl group necessary for RNA chain extension, it terminates the polymerization of the viral RNA chain after being incorporated, thus effectively inhibiting the replication of FCoV and preventing the virus from producing new infectious virions.
Derived from remdesivir, GS-441524 is the primary metabolite that exerts antiviral effects in the body, with a half-life of 24 hours in mammals. This pharmacokinetic property enables GS-441524 to maintain a stable and effective drug concentration in the cat's body after a single administration, providing a continuous antiviral effect. In the treatment of FIP, GS-441524 can not only directly inhibit the replication of FCoV in infected cells but also reduce the viral load in the cat's body, thereby alleviating the excessive immune response and tissue damage caused by viral infection, and creating favorable conditions for the cat's immune system to exert its antiviral effect.
About Cat FIP:
Feline Infectious Peritonitis (FIP) is a severe systemic viral disease that is highly fatal to cats, caused by the mutation of pathogenic strains of feline coronavirus (FCoV). FCoV is a member of the Coronaviridae family, which is widely distributed in global cat populations, and the infection rate is relatively high in multi-cat breeding environments. The virus is mainly transmitted through the fecal-oral route, and cats can be infected by ingesting food or water contaminated with FCoV, or by contacting contaminated cat litter and utensils.
The occurrence of FIP is closely related to the immune function of cats. For cats with a normal and robust immune system, after FCoV infection, the virus is usually limited to the intestinal tract, and the body can clear the virus through the mucosal immune system, without developing FIP. However, for young cats (especially those under 6 months old), elderly cats, or cats with immune function suppressed by other diseases or stress factors, FCoV will mutate in the body, and the mutated virus has the ability to invade the mononuclear phagocyte system, spread to various tissues and organs through the blood circulation, and induce a series of pathological changes, leading to the occurrence of FIP.
Clinically, FIP is divided into two main types: effusive (wet) FIP and non-effusive (dry) FIP. Effusive FIP is characterized by the accumulation of protein-rich exudate in the abdominal cavity, thoracic cavity, or pericardial cavity, resulting in abdominal distension, dyspnea and other symptoms in cats; non-effusive FIP is manifested as the formation of granulomatous lesions in the liver, kidney, spleen, lymph nodes and other organs, and the clinical symptoms are related to the location and severity of the lesions. Common systemic symptoms of FIP include persistent fever unresponsive to antibiotic treatment, progressive weight loss, loss of appetite, and mental depression. Some cats may also have ocular symptoms (such as uveitis) and neurological symptoms (such as ataxia, seizures).
The diagnosis of FIP is challenging due to the lack of specific clinical signs and laboratory tests. Clinicians usually make a preliminary diagnosis based on the cat's epidemiological history, clinical manifestations, blood biochemistry (elevated globulin, hypoalbuminemia), and fluid examination (for effusive FIP). Definitive diagnosis can be made by histopathological examination or viral nucleic acid detection. At present, the prevention of FIP is mainly focused on reducing the infection risk of FCoV, including maintaining a clean feeding environment, reducing the density of cat breeding, avoiding stress stimulation, and improving the immune function of cats. The existing FIP vaccines have not been widely recognized due to their limited efficacy.
Applications of GS441524:
GS-441524 is an antiviral preparation mainly used for the off-label treatment of feline infectious peritonitis in clinical veterinary practice, and its application is aimed at cats that have been clinically diagnosed with FIP and have no obvious contraindications to the drug. The dosage of GS-441524 injection is mainly determined according to the cat's body weight and the clinical type of FIP, and the dosage needs to be appropriately increased for cats with ocular or neurological involvement and recurrent cases. The drug is administered by injection, and the treatment course and dosage adjustment need to be carried out under the guidance of a professional veterinarian according to the cat's clinical response and physical condition during the treatment period.
Recommended dosage:
FIP(Wet): 0.3ml/kg * body weight kg + 0.1ml residue
FIP (Dry): 0.4ml/kg * body weight kg + 0.1ml residue
Eye / nerve entry: 0.5ml/kg * body weight kg + 0.1ml residue
Recurrence: 0.6 ml / kg * body weight kg + 0.1ml residue
Shipping:
